EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Challenges for the improvement of valganciclovir prophylaxis in solid organ transplantation and the possible role of therapeutic drug monitoring in adults

Lukas K van Vugt, Dennis A Hesselink iD, Brenda C M de Winter iD

British Journal of Clinical Pharmacology · 2025-06 · 91 (6) · 1551-1559

DOI: 10.1111/bcp.16138 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 18.06.2024. Verfasst von Lukas K van Vugt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus MC Transplant Institute, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Antiviral Agents, Organ Transplantation, Cytomegalovirus Infections, Drug Monitoring. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytomegalovirus (CMV) infection frequently occurs after solid organ transplantation and is associated with an increased morbidity and mortality. Fortunately, the development of valganciclovir prophylaxis has lowered the incidence of CMV infection and its complications in immunosuppressed solid organ transplant recipients. However, breakthrough infections during valganciclovir prophylaxis and late CMV infection after cessation of valganciclovir prophylaxis still occur with the current prophylactic strategy. Additionally, valganciclovir resistance has emerged among CMV strains, which complicates the treatment of CMV infections. Furthermore, the use of valganciclovir is associated with myelotoxicity, which can lead to the premature withdrawal of prophylaxis. It is important to address these current issues in order to improve the standard care after solid organ transplantation. This paper will therefore discuss the clinical practice of valganciclovir prophylaxis, elaborate on its issues and suggest how to improve the current prophylactic strategy with a possible role for therapeutic drug monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsOrgan TransplantationCytomegalovirus InfectionsDrug MonitoringGanciclovirHumansValganciclovirAdultImmunocompromised HostDrug Resistance, ViralCytomegalovirus

Stichwörter der Autor:innen

ganciclovirsolid organ transplantationtherapeutic drug monitoringvalganciclovir

Substanzen

ValganciclovirAntiviral AgentsGanciclovir

Autor:innen und Institutionen

  • Erasmus MC Transplant Institute, Rotterdam, the Netherlands.
  • Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Centre Rotterdam, the Netherlands.
  • Department of Hospital Pharmacy, Erasmus MC, University Medical Centre Rotterdam, the Netherlands.

ORCID-Profile: Dennis A Hesselink, Brenda C M de Winter

Zitieren

APA

van Vugt, L. K., Hesselink, D. A., & de Winter, B. C. M. (2025). Challenges for the improvement of valganciclovir prophylaxis in solid organ transplantation and the possible role of therapeutic drug monitoring in adults. British Journal of Clinical Pharmacology, 91(6), 1551-1559. https://doi.org/10.1111/bcp.16138

Vancouver

van Vugt LK, Hesselink DA, de Winter BCM. Challenges for the improvement of valganciclovir prophylaxis in solid organ transplantation and the possible role of therapeutic drug monitoring in adults. British Journal of Clinical Pharmacology. 2025;91(6):1551-1559. doi:10.1111/bcp.16138

BibTeX
@article{vanVugt2025,
  author = {van Vugt, Lukas K and Hesselink, Dennis A and de Winter, Brenda C M},
  title = {Challenges for the improvement of valganciclovir prophylaxis in solid organ transplantation and the possible role of therapeutic drug monitoring in adults},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {6},
  pages = {1551--1559},
  doi = {10.1111/bcp.16138}
}
Kostenlos starten →